• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • MANUFACTURERS
  • HEADHUNTERS
  • PRODUCT SECTIONS
  • COMPANIES

SPINEMarketGroup

Spine Industry News

  • HOME
  • 2025
  • 2024
  • BROCHURES
  • ARTICLES
  • VIDEOS

Geisinger Health Plan Announces Exclusive Coverage for the iFuse Implant System® for SI Joint Fusion

June 15, 2016 By SPINEMarketGroup

SAN JOSE, Calif., June 15, 2016 /PRNewswire/ — SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System® (“iFuse”), a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, announced that Geisinger Health Plan, a commercial health plan covering more than 500,000 lives in the states ofDelaware, Maine, New Jersey, Pennsylvania, and West Virginia has issued a revised medical policy for SI joint fusion that exclusively covers the iFuse Implant System “for the treatment of SI joint syndrome and SI joint mediated mechanical low back pain” when the five diagnostic criteria recommended by the International Society for the Advancement of Spine Surgery (ISASS) are met. The policy becomes effective June 15, 2016, and  further states: “the use of minimally invasive fusion products other than iFuse Implant System for sacroiliac joint fusion is considered experimental/investigational or unproven and therefore NOT COVERED.” The complete policy can be found at:https://www.thehealthplan.com/

Geisinger’s exclusive iFuse coverage policy further distinguishes iFuse from all other SI joint fusion technologies which are predominantly round, screw-based systems.

iFuse’s unique patented triangular shape provides 31 times the rotational resistance of a screw. It is the only commercially available SI joint fusion device in the United States with published evidence that demonstrates safety, effectiveness and economic benefits, including three large multicenter prospective studies, two of which are randomized controlled trials (RCTs). Currently, there are more than 40 peer reviewed publications supporting positive clinical outcomes, safety, biomechanics, and the economic value of iFuse. It is the only SI joint fusion product with a unique FDA clearance recognizing that clinical studies demonstrate improved pain, patient function and quality of life.

“Payors are increasingly requiring robust safety and effectiveness evidence, to include prospective and randomized controlled trials, that demonstrate significant patient improvement and long-term durability. iFuse is clearly the ONLY MIS SI joint fusion technology supported by prospective studies, including two RCTs, that demonstrate significant patient improvement and long-term durability; hence, we are seeing innovative leading-edge payors like Geisinger make iFuse the ONLY MIS SI joint fusion option available for their health plan members,” said Michael Mydra, Vice President, Health Outcomes & Reimbursement, SI-BONE.

“I am very pleased to see the Geisinger Health Plan establish an exclusive coverage policy for iFuse based on the strength of clinical and economic evidence,” said Dr. Matthew R. Eager, from Pennsylvania.  “This decision provides an important treatment option for patients who fail to respond to non-surgical treatment for various SI joint conditions and will reduce the need for costly repeated interventions. I appreciate the health plans medical directors’ willingness to discuss this specific treatment with me and consider this important policy change. I hope other health plans follow Geisinger’s lead and establish exclusive coverage policies for iFuse to provide this important clinically proven technology to those patients suffering from certain types of SI joint dysfunction.”

About SI-BONE, Inc.
SI-BONE, Inc. (San Jose, California) is a leading sacroiliac joint medical device company dedicated to the development of tools and products for patients with low back issues related to certain SI joint disorders. The company develops, manufactures and markets minimally invasive products for the SI joint. SI-BONE, Inc. received original 510(k) clearance in November 2008 from the Food and Drug Administration (FDA) to market its iFuse Implant System. The CE mark for European commercialization was obtained in November 2010.

The iFuse Implant System is a minimally invasive surgical option that uses titanium implants coated with a porous, titanium plasma spray (TPS) that acts as an interference surface, designed to help decrease implant motion, and allow for biological fixation to support long term fusion. The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. Clinical studies have demonstrated that treatment with the iFuse Implant System improved pain, patient function, and quality of life. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit. For information about the risks, visit: www.si-bone.com/risks.

(Visited 11 times, 2 visits today)

Filed Under: NEWS Tagged With: 2016, NEWS

Primary Sidebar

PLATINUM SPONSORS

GOLD SPONSORS

MOST POPULAR POSTS

  • BROCHURES
  • Just Reflective, Not Disappointed: Globus Medical’s…
  • What’s Happening with Globus Medical? Why Has the…
  • (UPDATED 2025): 6 Artificial Cervical Discs You’ll…
  • The Crown Is Still Medtronic’s… For Now!
  • (UPDATED 2024): +8 Lumbar Artificial Discs to Know…
  • Stryker’s Spine Business Sale: A Smart Move or a…
  • Globus Medical to Execute $500 Million Share Buyback…
  • Globus Medical extends versatility of Advanced…
  • Eminent Spine’s 3D Printed Titanium Pedicle Screw…
  • Dispute Over Spinal Implant Royalties Between…
  • M6 Discontinued: What Are the Alternatives for a…
  • Orthofix Discontinues M6-C™ and M6-L™ Artificial…
  • Alphatec Today: Where It Stands and Where It’s Heading?
  • (Updated!) 15 Expandable PLIF Cages to Know…!
  • (UPDATED 2024): +108 Stand-Alone Cervical Cages to Know..!
  • After Diabetes, Could Medtronic’s Spine…
  • Stryker’s Spine Exit: What It Means for…
  • Globus Medical Reports First Quarter 2025 Results
  • Why Didn’t Globus Medical’s Stock Rise After…
  • LAST 10 VIDEOS PUBLISHED

    1. Biedermann Motech: MOSS 100 (Short)
    2. POWEHI MEDICAL AG: KUDOS™ Modular
    3. POWEHI MEDICAL AG: TANTO® Screw
    4. Syntropiq: Taurus TLIF (Short)
    5. LEM Surgical: Dynamis Surgical Robot
    6. Aegis Spine:PathLoc-TA
    7. NGMedical: MOVE®-C Artificial Disc
    8. B.Braun Aesculap: Ennovate® Cervical MIS
    9. Spineart: PERLA® TL Deformity Solutions
    10. NGMedical: MOVE®-C

    Recent Comments

    • Peter on A New Player in Spinal Care, POWEHI Medical!
    • Sandy on Just Reflective, Not Disappointed: Globus Medical’s Bittersweet Q1 2025
    • SPINEMarketGroup on M6 Discontinued: What Are the Alternatives for a Cervical Artificial Disc?
    • Sergio López-Fombona on M6 Discontinued: What Are the Alternatives for a Cervical Artificial Disc?
    • Drew on Has Globus Already Surpassed Medtronic in the Spine Market? Can J&J Find Its Way Back to the Top?
    • Ahmed Hassan El-Naggary on Has Globus Already Surpassed Medtronic in the Spine Market? Can J&J Find Its Way Back to the Top?
    • Email
    • Twitter
    • YouTube

    Subscribe to Our Newsletter!

    Check your inbox or spam folder to confirm your subscription.

    Footer

    • Email
    • Twitter
    • YouTube

    Contact us:

    [email protected] [email protected]

    PRIVATE POLICY

    • Legal Advice
    • Embed Link
    • VIDEOS

    Copyright © 2025 · SPINEMarketGroup

    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
    View preferences
    {title} {title} {title}